All News Altimmune, Inc.

Equities

ALT

US02155H2004

Real-time Estimate Cboe BZX Other stock markets 02:41:46 2024-05-02 pm EDT			5-day change	1st Jan Change
7.19 ^USD	+1.70%		-0.42%	-36.27%

Apr. 30	North American Morning Briefing : More Earnings -2-	DJ
Apr. 29	Altimmune Shares Decline After Guggenheim Downgrade	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024	07:31am	AQ
Altimmune to Participate at Two Upcoming Conferences	May. 01	AQ
North American Morning Briefing : More Earnings -2-	Apr. 30	DJ
Altimmune Shares Decline After Guggenheim Downgrade	Apr. 29	MT
Guggenheim Downgrades Altimmune to Neutral From Buy	Apr. 29	MT
Altimmune Statement on the Passing of Dr. Stephen Harrison	Apr. 25	AQ
Transcript : Altimmune, Inc. - Special Call	Apr. 02
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	Mar. 27	MT
Transcript : Altimmune, Inc., Q4 2023 Earnings Call, Mar 27, 2024	Mar. 27
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q4 Revenue $37,000	Mar. 27	MT
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 27	AQ
Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024	Mar. 20	AQ
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Altimmune, Inc.(NasdaqGM:ALT) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT	Mar. 05	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT	Mar. 03	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Altimmune, Inc.

Equities

ALT

US02155H2004

All News

Filters